Background: ALK is a prognostic and predictive tumor marker in non-small cell lung carcinoma (NSCLC), and is more often found in lung adenocarcinomas. Conclusions:The efficacy of crizotinib in patients with advanced NSCLC is related to the number of metastatic organs, age and timing of treatment. The use of crizotinib is prone to intracranial progression, and progression of simple brain metastases is not an indication that crizotinib is discontinued. Patients will continue to benefit from combination of local radiotherapy. READ ARTICLE
Pathology - Research and Practice DOI:10.1016/j.prp.2019.152695
Authors: Huiyan Deng, Bin Li, Lina Li, Jingcui Peng, Tongshuai Lv, Yueping Liu, CuiminDing
